Lavipharm
ATH:LAVI · GRS246003008
PharmaceuticalsSmall
360
44
Medium confidence — indicative
Value40
Quality—
Growth66
Safety43
Sentiment43
Value Creation13/20creating some value
- Creates more value than its capital costs
- Owner earnings growing
- Owner earnings per share growing
- Reinvests at strong returns
- Solid earnings base
What this means
Lavipharm clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.
Based on 3/5 components.
Profile
CountryLuxembourg
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeATSE
Founded1975
Employees146
Websitelavipharm.com
ISINGRS246003008
Last UpdateApr 2, 2026
Indices
Themes
UrologyCannabisCardiovascularPain ManagementCentral Nervous SystemOncologyPharmaceutical
Description
Analysis
Middle-of-the-road
Lavipharm S.A. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.
360° rank · history
1007550250
32
2026
All-time high
32
Mar 2026
All-time low
32
Mar 2026
Average rank
32
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.
Similar Stocks
The companies this stock is ranked against.
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100